Shilpa plans $50 million phased peptide manufacturing expansion
Industry reporting · BioPharm International
Source published: · Event / reporting date: 2026-11-03
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What changed
BioPharm International reported Shilpa CDMO's plan to invest $50 million in peptide manufacturing at Raichur, India. The phased expansion would add 10 kiloliters of solid-phase synthesis reactor capacity, beginning with a commercial line planned for December 2026. Commercial supply is expected to ramp during 2027; these are planned capabilities rather than demonstrated utilization.
Why it may matter
Analysis: Additional synthesis and purification capacity may broaden sourcing options for complex peptides; qualification timelines and customer commitments still matter.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections